Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $124.91 on Friday. The company has a market capitalization of $154.97 billion, a PE ratio of 19.37, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a 52-week low of $91.68 and a 52-week high of $128.70. The company has a 50-day simple moving average of $123.36 and a 200 day simple moving average of $118.06.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 48.99%.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Gilead Sciences in the second quarter worth $2,150,268,000. Ameriprise Financial Inc. grew its position in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after buying an additional 5,392,191 shares in the last quarter. Invesco Ltd. increased its stake in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after acquiring an additional 2,169,266 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $238,083,000. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several recent research reports. Sanford C. Bernstein set a $135.00 price objective on Gilead Sciences and gave the stock an “outperform” rating in a report on Monday, December 29th. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. BMO Capital Markets reissued an “outperform” rating on shares of Gilead Sciences in a research report on Tuesday. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. Finally, Royal Bank Of Canada reduced their price objective on shares of Gilead Sciences from $105.00 to $100.00 and set a “sector perform” rating for the company in a research note on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $133.16.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.